Melanocyte-specific immune response in a patient with multiple regressing nevi and a history of melanoma

Anticancer Research

Volumn 31, Issue 11, 2011, Pages 3697-3703

  Speeckaert, Reinhart ^a   Van Geel, Nanja ^a   Luiten, Rosalie M ^b   Van Gele, Mireille ^a   Speeckaert, Marijn ^a   Lambert, Jo ^a   Vermaelen, Karim ^a   Tjin, Esther P M ^b   Brochez, Lieve ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Dysplastic nevi; Immune response; Melanocyte; Melanoma; Regression

Indexed keywords

GLYCOPROTEIN GP 100; HLA A2 ANTIGEN; MELAN A; MONOPHENOL MONOOXYGENASE;

ADULT; ANTIGEN SPECIFICITY; ARTICLE; CANCER RISK; CASE REPORT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DYSPLASTIC NEVUS; FLOW CYTOMETRY; HIGH RISK PATIENT; HISTORY; HUMAN; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IMMUNOSURVEILLANCE; LYMPHOCYTIC INFILTRATION; MALE; MELANOCYTE; MELANOMA; PRIORITY JOURNAL; T LYMPHOCYTE;

BLOTTING, WESTERN; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DYSPLASTIC NEVUS SYNDROME; FLOW CYTOMETRY; GP100 MELANOMA ANTIGEN; HLA-A2 ANTIGEN; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MART-1 ANTIGEN; MELANOCYTES; MELANOMA; MIDDLE AGED; MONOPHENOL MONOOXYGENASE; SKIN NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; VITILIGO;

EID: 83055187104     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Rhodes AR: Neoplasms, benign neoplasias, hyperplasias and dysplasias of melanocytes. In: Dermatology in General Medicine, 4th edn. Fitzpatrick TB, Eisen AZ, Wolff K, Freedberg IM, Austen KF (eds.) New York, McGraw-Hill, pp. 996-1077, 1993.
2. van Geel N, Vandenhaute S, Speeckaert R, Brochez L, Mollet I, De Cooman L and Lambert J: Prognostic value and clinical significance of halo nevi regarding vitiligo. Br J Dermatol 164: 743-749, 2011.
3. Ortonne JP, Mosher DB and Fitzpatrick TB: Vitiligo and other hypomelanoses of hair and skin. In: Topics in Dermatology. Ortonne JP, Mosher DB, Fitzpatrick TB (eds.) New York, Plenum Press, pp. 567-611, 1983.
4. Barnhill RL, Cerroni L, Cook M, Elder DE, Kerl H, LeBoit PE, McCarthy SW, Mihm MC, Mooi WJ, Piepkorn MW, Prieto VG and Scolyer RA: State of the art, nomenclature, and points of consensus and controversy concerning benign melanocytic lesions: outcome of an international workshop. Adv Anat Pathol 17: 73-90, 2010.
5. Benz G, Holzel D and Schmoeckel C: Inflammatory cellular infiltrates in melanocytic nevi. Am J Dermatopathol 13: 538-542, 1991.
6. Musette P, Bachelez H, Flageul B, Delarbre C, Kourilsky P, Dubertret L and Gachelin G: Immune-mediated destruction of melanocytes in halo nevi is associated with the local expansion of a limited number of T-cell clones. J Immunol 162: 1789-1794, 1999. (Pubitemid 29307059)
7. Halpern AC, Guerry D 4th, Elder DE, Clark WH Jr, Synnestvedt M, Norman S and Averle R: Dysplastic nevi as risk markers of sporadic (nonfamilial) melanoma. A case control study. Arch Dermatol 127: 995-999, 1991.
8. Takeuchi H, Kuo C, Morton DL, Wang HJ and Hoon DSB: Expression of differentiation melanoma-associated antigen genes is associated with favorable disease outcome in advanced-state melanoma. Cancer Res 63: 441-448, 2003 (Pubitemid 36152505)
9. Hussein MR, Elsers DA, Fadel SA and Omar HE: Immunohistological characterization of tumour-infiltrating lymphocytes in melanocytic skin lesions. J Clin Pathol 59: 316-324, 2006. (Pubitemid 43344897)
10. Clark RA, Chong BF, Mirchandani N, Yamanaka K, Murphy GF, Dowgiert RK and Kupper TS: A novel method for the isolation of skin-resident T-cells from normal and diseased human skin. J Invest Dermatol 126: 1059-1070, 2006.
11. van den Boorn JG, Konijnenberg D, Dellemijn TA, van der Veen JP, Bos JD, Melief CJ, Vyth-Dreese FA and Luiten RM: Autoimmmune destruction of skin melanocytes by perilesional T-cells from vitiligo patients. J Invest Dermatol 129: 2220-2232, 2009.
12. Hofmann UB, Bröcker EB and Hamm H: Simultaneous onset of segmental vitiligo and a halo surrounding a congenital melanocytic naevus. Acta Derm Venereol 89: 402-406, 2009.
13. Baranda L, Torres-Alvarez B, Moncada B, Portales-Pérez D, de la Fuente H, Layseca E and González-Amaro R: Presence of activated lymphocytes in the peripheral blood of patients with halo nevi. J Am Acad Dermatol 41: 567-572, 1999. (Pubitemid 29480405)
14. Halpern AC, Schuchter LM, Elder DE, Geurry D 4th, Elenitsas R, Trock B and Matozzo I: Effects of topical tretinoin on dysplastic nevi. J Clin Oncol 12: 1028-1035, 1994. (Pubitemid 24145333)
15. Kato Y, Salumbides BC, Wang XF, Qian DZ, Williams S, Wei Y, Sanni TB, Atatdja P and Pili R: Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma. Mol Cancer Ther 6: 70-81, 2007. (Pubitemid 46206669)
16. Liu X, Chan SY and Ho PS: Comparison of the in vitro and in vivo effects of retinoids either alone or in combination with cisplatin and 5-fluorouracil in tumor development and metastasis in melanoma. Cancer Chemother Pharmacol 63: 167-174, 2008.
17. Nakai N, Hartmann G, Kishimoto S and Katoh N: Dendritic cell vaccination in human melanoma: relationships between clinical effects and vaccine parameters. Pigment Cell Melanoma Res 23: 607-619, 2010.
18. Engelhard VH, Bullock TN, Colella TA, Sheasley SL and Mullins DW: Antigens derived from melanocyte differentiation proteins: self-tolerance, autoimmunity and use for cancer immunotherapy. Immunol Rev 188: 136-146, 2002. (Pubitemid 35398871)
19. Jacobs JFM, Aarntzen EH, Sibelt LA, Blokx WA, Boullart AC, Gerritsen MJ, Hoogerbrugge PM, Figdor CG, Adema GJ, Punt CJ and de Vries IJ: Vaccine-specific local T-cell reactivity in immunotherapy-associated vitiligo in melanoma patients. Cancer Immunol Immunother 58: 145-151, 2009.
20. Cassarino DS, Miller WJ, Auerbach A, Yang A, Sherry R and Duray PH: The effects of gp100 and tyrosinase peptide vaccinations on nevi in melanoma patients. J Cutan Pathol 33: 335-342, 2006.
21. Rongioletti F, Cecchi F and Rebora A: Halo phenomenon in melanocytic nevi (Sutton's nevi). Does the diameter matter? J Eur Acad Dermatol Venereol 25: 1231-1232, 2011.
22. Palermo B, Campanelli R, Garbelli S, Mantovani S, Lantelme E, Brazzelli V, Ardigó M, Borroni G, Martinetti M, Bardulli C, Necker A and Giachino C: Specific cytotoxic T lymphocyte responses against Melan-A/MART1 tyrosinase and gp100 in vitiligo by the use of major histocompatibility complex/peptide tetramers: the role of cellular immunity in the etiopathogenesis of vitiligo. J Invest Dermatol 117: 326-332, 2001. (Pubitemid 34205718)
23. Mandelcom-Monson RL, Shear NH, Yau E, Sambhara S, Barber BH, Spaner D and DeBendedette MA: Cytotoxic T lymphocyte reactivity to gplOO, MelanA/MART-1, and tyrosinase, in HLA-A2-positive vitiligo patients. J Invest Dermatol 121: 550-556, 2003. (Pubitemid 37072267)
24. Yamaguchi Y and Hearing VJ: Physiological factors that regulate skin pigmentation. Biofactors 35: 193-199, 2009.
25. Ogg GS, Rod Dunbar P, Romero P, Chen JL and Cerundolo V: High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo. J Exp Med 188: 1203-1208, 1998. (Pubitemid 28443344)
26. van Geel NA, Mollet IG, De Schepper S, Tjin EP, Vermaelen K, Clark RA, Kupper TS, Luiten RM and Lambert J: First histopathological and immunophenotypic analysis of early dynamic events in a patient with segmental vitiligo with halo nevi. Pigment Cell Melanoma Res 23: 375-384, 2010.
27. Lane C, Leitch J, Tan X, Hadjati J, Bramson JL and Wan Y: Vaccination-induced autoimmune vitiligo as a consequence of secondary trauma to the skin. Cancer Res 64: 1509-1514, 2004. (Pubitemid 38235624)